{"id":3666,"date":"2025-03-31T18:11:47","date_gmt":"2025-03-31T18:11:47","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/adenosine-txt\/"},"modified":"2025-03-31T18:11:47","modified_gmt":"2025-03-31T18:11:47","slug":"adenosine-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/adenosine-txt\/","title":{"rendered":"Adenosine.txt"},"content":{"rendered":"

Adenosine<\/h1>\n

CLINICAL USE <\/H3><\/p>\n
  • Rapid reversion to sinus rhythm of\n

    paroxysmal supraventricular tachycardias<\/p>\n

  • Diagnosis of broad or narrow complex\n

    supraventricular tachycardias
    \n

    DOSE IN NORMAL RENAL FUNCTION <\/H3>
    \nInitially: 3 mg over 2 seconds with cardiac
    \nmonitoring followed, if necessary, by 6 mg
    \nafter 1\u20132 minutes and then by 12 mg after a
    \nfurther 1\u20132 minutes
    \n

    PHARMACOKINETICS <\/H3>
    \n
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n267.2\n<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \n0\n<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp :
    \n<5\n<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :
    \nNo data\n<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : seconds\/
    \nUnchanged
    \n

    DOSE IN RENAL IMPAIRMENT <\/H3>
    \n

    GFR (mL\/MIN)<\/H4>
    \n
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
    \n
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
    \n
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nDose as in normal renal function
    \n

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
    \n
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:
    \nNot dialysed. Dose as in normal renal function<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :
    \nNot dialysed. Dose as in normal renal function
    \n
  • HDF\/high flux &nbsp :
    \nUnknown dialysability. Dose as in
    \nnormal renal function
    \n
  • CAV\/VVHD &nbsp &nbsp &nbsp:
    \nNot dialysed. Dose as in normal renal function
    \n

    IMPORTANT DRUG INTERACTIONS <\/H3>
    \nPotentially hazardous interactions with other drugs<\/p>\n
  • Anti-arrhythmics: increased risk of\n

    myocardial depression<\/p>\n

  • Antipsychotics: increased risk\n

    of ventricular arrhythmias with
    \nantipsychotics that prolong the QT
    \ninterval<\/p>\n

  • Beta-blockers: increased risk of myocardial\n

    depression<\/p>\n

  • Effect is enhanced and extended by\n

    dipyridamole; therefore if use of adenosine
    \nis essential, dosage should be reduced by a
    \nfactor of 4 (i.e. initial dosage of 0.5\u20131 mg)<\/p>\n

  • Theophylline and other xanthines are\n

    potent inhibitors of adenosine
    \n

    ADMINISTRATION <\/H3>
    \n

    Reconstition<\/H4>
    \n \u2013<\/p>\n

    Route <\/H4>
    \nIV<\/p>\n

    Rate of Administration <\/H4>
    \nRapid IV bolus (see dose)<\/p>\n

    Comments<\/H4>
    \nDo not refrigerate<\/p>\n

    Administer into central vein, large <\/p>\n

    peripheral vein, or into an IV line. If IV
    \nline used, follow dose by rapid sodium
    \nchloride 0.9% flush
    \n

    OTHER INFORMATION <\/H4><\/p>\n
  • Neither the kidney nor the liver is\n

    involved in the degradation of exogenous
    \nadenosine, so dose adjustments are not
    \nrequired in hepatic or renal insufficiency<\/p>\n

  • Unlike verapamil, adenosine may be used\n

    in conjunction with a beta-blocker<\/p>\n

  • Common side effects: facial flushing, chest\n

    pain, dyspnoea, bronchospasm, nausea
    \nand lightheadedness; the side effects are
    \nshort-lived<\/p>\n","protected":false},"excerpt":{"rendered":"

    Adenosine CLINICAL USE Rapid reversion to sinus rhythm of paroxysmal<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-3666","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=3666"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/3666\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=3666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=3666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=3666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}